Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin

American Heart Journal

Volumn 140, Issue 1, 2000, Pages 67-73

  Bhatt, Deepak L ^a   Hirsch, Alan T ^b   Ringleb, Peter A ^c   Hacke, Werner ^c   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ANGINA PECTORIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETREATMENT; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 0033941958     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.108239     Document Type: Article

References (44)

1. Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. Circulation 1998;98:1860-8.
2. Fuster V. Epidemic of cardiovascular disease and stroke: the three main challenges. Circulation 1999;99:1132-7.
3. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. BMJ 1988;296:320-31.
4. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
5. Clopidogrel for reduction of atherosclerotic events. Med Lett Drugs Ther 1998;40:59-60.
6. Coukell AJ, Markham A. Clopidogrel. Drugs 1997;54:745-50.
7. Gent M. Benefit of clopidogrel in patients with coronary disease [abstract]. Circulation 1997;96:1-467.
8. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
9. Humbert M, Nurden P, Bihour C, et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vase Biol 1996;16:1532-43.
10. CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
11. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. JAMA 1999;281:806-10.
12. ISIS-2 collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
13. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-50.
14. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-6.
15. Poggio ED, Kottke-Marchant K, Welsh PA, et al. The prevalence of aspirin resistance in cardiac patients as measured by platelet aggregation and the PFA-100 [abstract]. J Am Coll Cardiol 1999;33:254A.
16. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation 1998;98:757-65.
17. Peterson J, Lauer MS, Lincoff AM, et al. Evidence for a potential adverse interaction between aspirin and angiotensin converting enzyme inhibitors after percutaneous coronary angioplasty: the EPI-LOG trial [abstract]. J Am Coll Cardiol 1999;33:397A.
18. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-7.
19. Savi P, Bernat A, Dumas A, et al. Effect of aspirin and clopidogrel on platelet-dependent tissue factor expression in endothelial cells. Thromb Res 1994;73:117-24.
20. American Heart Association. American Heart Association 2000 statistics. 10 Feb 2000. Available from URL:http//www.americanheart.org/
21. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. Circulation 1998;97:1702-7.
22. The SYMPHONY investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet 2000;355:337-45.
23. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997;157:99-104.
24. Wolinsky FD, Smith DM, Stump TE, et al. The sequelae of hospitalization for congestive heart failure among older adults. J Am Geriatr Soc 1997;45:558-63.
25. Bums RB, McCarthy EP, Moskowitz MA, et al. Outcomes for older men and women with congestive heart failure. J Am Geriatr Soc 1997;45:276-80.
26. HerlitzJ, Brandmp G, Caidahl K, et al. Death, mode of death, morbidity and requirement for rehospitalization during 2 years after coronary artery bypass grafting in relation to preoperative ejection fraction. Coron Artery Dis 1996;7:807-12.
27. Rich MW, Vinson JM, Sperry JC, et al. Prevention of readmission in elderly patients with congestive heart failure: results of a prospective, randomized pilot study. J Gen Intern Med 1993;8:585-90.
28. Mark DB. Economics of treating heart failure. Am J Cardiol 1997;80:33H-38H.
29. Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998;82:465-9.
30. Belardinelli R, Georgiou D, Cianci G, et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999;99:1173-82.
31. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
32. Young JB, Gheorghiade M, Uretsky BF, et al. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. J Am Coll Cardiol 1998;32:686-92.
33. Selby JV, Fireman BH, Lundstrom RJ, et al. Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization. N Engl J Med 1996;335:1888-96.
34. Cohen DJ, Krumholz HM, Sukin CA, et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. Circulation 1995;92:2480-7.
35. Conti CR. Unstable angina: cost of conservative and invasive strategies using TIMI 3B as a model. Clin Cardiol 1995;18:187-8.
36. Smith NL, Reiber GE, Psaty BM, et al. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina. J Am Coll Cardiol 1998;32:1305-11.
37. Anand SS, Yusuf S, Pogue J, et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 1998;98:1064-70.
38. Maynard C. Rehospitalization in surviving patients of out-of-hospital ventricular fibrillation (the CASCADE study). Cardiac Arrest in Seattle: Conventional Amiodarone Drug Evaluation. Am J Cardiol 1993;72:1295-300.
39. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
40. Cannon CP, Weintraub WS, Demopoulos LA, et al. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Am J Cardiol 1998;82:731-6.
41. Newby LK. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Am Heart J 1999;138:210-8.
42. Braunwald E, Cannon CP, McCabe CH. An approach to evaluating thrombolytic therapy in acute myocardial infarction. The "unsatisfactory outcome" end point. Circulation 1992;86:683-7.
43. Albers GW. Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients? Neurology 2000;54:1022-8.
44. Harker LA, Marzec UM, Kelly AB, et al. Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998;98:2461-9.